Blood, Stem Cells and Cancer Research, St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
Mol Cancer. 2012 Feb 20;11:8. doi: 10.1186/1476-4598-11-8.
Acute myeloid leukaemia (AML) with nucleophosmin-1 (NPM1) mutation is a major subtype of AML. The NPM1 mutation induces a myeloproliferative disorder, but evidence indicates that other insults are necessary for the development of AML. We utilised microRNA microarrays and functional assays to determine if microRNA dysregulation could be involved in the pathogenesis of in NPM1 mutated (NPM1mut)-AML.
We used a stringent locked nucleic acid (LNA) based microRNA microarray platform to profile bone marrow samples of patients with normal karyotype AML. A panel of five microRNAs dichotomised AML patients according to their NPM1 mutational status. miR-10a, let-7b and let-7c were significantly over-expressed, while miR-130a and miR-335 were under-expressed in NPM1mut-AML when compared to NPM1wildtype-AML. Of these, miR-10a is the most differentially expressed in NPM1mut-AML versus NPM1wildtype-AML (> 10 fold higher as confirmed by qRT-PCR). To investigate the functions of miR-10a, the OCI-AML3 cell line was utilised, which is the only commercially available cell line bearing NPM1mut. OCI-AML3 cells were firstly demonstrated to have a similarly high miR-10a expression to primary NPM1mut-AML patient samples. Inhibition of miR-10a expression by miRCURY LNA Inhibitors (Exiqon) in these cells resulted in increased cell death as assessed by MTS, cell cycle and Annexin-V assays and reduced clonogenic capacity, indicative of an involvement in leukaemic cell survival. In silico filtering of bioinformatically predicted targets of miR-10a identified a number of potential mRNA targets with annotated functions in haematopoiesis, cell growth and apoptosis. Lucferase reporter assays confirmed a number of these putative tumorogenic genes that are miR-10a suppressible including KLF4 and RB1CC1. This provides a potential mechanism for the pathogenic role of miR-10a in NPM1mut-AML.
This study provides, for the first time, in vitro evidence of a pro-survival role of miR-10a in NPM1mut-AML, that it may contribute to the pathogenesis of NPM1mut-AML and identifies putative tumorogenic targets.
核磷蛋白 1(NPM1)突变的急性髓系白血病(AML)是 AML 的主要亚型之一。NPM1 突变可诱导骨髓增生异常,但有证据表明,其他损伤对于 AML 的发展是必要的。我们利用 microRNA 微阵列和功能测定来确定 microRNA 失调是否可能参与 NPM1 突变(NPM1mut)-AML 的发病机制。
我们使用严格的锁核酸(LNA)基于 microRNA 微阵列平台来分析正常核型 AML 患者的骨髓样本。一组五个 microRNA 根据其 NPM1 突变状态将 AML 患者分为两组。与 NPM1wt-AML 相比,NPM1mut-AML 中 miR-10a、let-7b 和 let-7c 明显过表达,而 miR-130a 和 miR-335 表达下调。其中,miR-10a 在 NPM1mut-AML 中表达差异最大(通过 qRT-PCR 证实 > 10 倍)。为了研究 miR-10a 的功能,我们利用了 OCI-AML3 细胞系,这是唯一具有 NPM1mut 的商业上可用的细胞系。首先证明 OCI-AML3 细胞与原发性 NPM1mut-AML 患者样本具有相似的高 miR-10a 表达。用 miR-10a 的 microRNA 抑制剂(Exiqon)抑制这些细胞中的 miR-10a 表达,通过 MTS、细胞周期和 Annexin-V 测定评估细胞死亡增加,并且集落形成能力降低,表明其参与白血病细胞存活。对 miR-10a 的生物信息学预测靶标的计算机过滤鉴定了一些具有造血、细胞生长和凋亡注释功能的潜在 mRNA 靶标。荧光素酶报告基因测定证实了其中一些潜在的致癌基因,即 miR-10a 可抑制,包括 KLF4 和 RB1CC1。这为 miR-10a 在 NPM1mut-AML 中的致病作用提供了一种潜在机制。
本研究首次提供了 NPM1mut-AML 中 miR-10a 具有促生存作用的体外证据,它可能有助于 NPM1mut-AML 的发病机制,并确定了潜在的致癌靶标。